| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BML Investment Partners, L.P. | 10% | $6,066,773 | 4,100,002 | BML Investment Partners, L.P. | 31 Dec 2024 |
As of 30 Sep 2025, 2 institutional investors reported holding 5,286 shares of Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL). This represents 0.01% of the company’s total 41,123,390 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 806 | $1,193 | $1.48 | 1 | |
| 2025 Q3 | 5,286 | $7,822 | $1.48 | 2 | |
| 2025 Q2 | 5,286 | $7,822 | -$72,397 | $1.48 | 2 |
| 2025 Q1 | 54,405 | $80,219 | -$27,599,327 | $1.48 | 5 |
| 2024 Q4 | 24,297,978 | $27,722,908 | -$94,040 | $1.14 | 21 |
| 2024 Q3 | 24,338,965 | $24,820,801 | +$1,848,962 | $1.02 | 22 |
| 2024 Q2 | 22,188,649 | $18,079,945 | -$1,749,977 | $0.82 | 26 |
| 2024 Q1 | 23,510,455 | $29,386,379 | +$2,669,497 | $1.25 | 31 |
| 2023 Q4 | 21,782,170 | $19,366,883 | -$363,258 | $0.89 | 19 |
| 2023 Q3 | 19,691,035 | $17,916,533 | -$91,084 | $0.91 | 16 |
| 2023 Q2 | 19,786,405 | $18,702,369 | -$522,912 | $0.95 | 16 |
| 2023 Q1 | 20,235,741 | $19,376,340 | -$1,268,448 | $0.96 | 16 |
| 2022 Q4 | 21,665,748 | $19,499,479 | -$7,998,675 | $0.90 | 21 |
| 2022 Q3 | 27,268,502 | $61,628,035 | +$234,013 | $2.26 | 25 |
| 2022 Q2 | 27,134,733 | $68,384,811 | +$1,415,523 | $2.52 | 23 |
| 2022 Q1 | 15,481,857 | $45,523,508 | -$4,266,786 | $2.94 | 21 |
| 2021 Q4 | 27,433,563 | $137,451,000 | -$12,949,488 | $5.01 | 28 |
| 2021 Q3 | 17,597,059 | $137,080,000 | -$11,368,450 | $7.79 | 19 |
| 2021 Q2 | 18,784,784 | $183,902,000 | +$18,216,534 | $9.79 | 29 |
| 2021 Q1 | 16,807,348 | $278,162,000 | +$278,162,000 | $16.55 | 29 |